U.S. Markets closed
  • S&P Futures

    4,382.50
    -29.25 (-0.66%)
     
  • Dow Futures

    34,902.00
    -72.00 (-0.21%)
     
  • Nasdaq Futures

    14,858.00
    -179.75 (-1.20%)
     
  • Russell 2000 Futures

    2,226.70
    -10.80 (-0.48%)
     
  • Crude Oil

    73.24
    -0.38 (-0.52%)
     
  • Gold

    1,832.40
    -3.40 (-0.19%)
     
  • Silver

    25.60
    -0.18 (-0.69%)
     
  • EUR/USD

    1.1888
    -0.0008 (-0.0713%)
     
  • 10-Yr Bond

    1.2690
    +0.0080 (+0.63%)
     
  • Vix

    17.70
    -0.61 (-3.33%)
     
  • GBP/USD

    1.3956
    -0.0002 (-0.0112%)
     
  • USD/JPY

    109.4800
    +0.0190 (+0.0174%)
     
  • BTC-USD

    40,139.09
    +247.53 (+0.62%)
     
  • CMC Crypto 200

    955.47
    +25.11 (+2.70%)
     
  • FTSE 100

    7,078.42
    +61.79 (+0.88%)
     
  • Nikkei 225

    27,343.30
    -439.12 (-1.58%)
     

CRISPR Therapeutics, Capsida Collaborate To Develop Gene-Edited Therapies For Neurological Diseases

·1 min read
  • CRISPR Therapeutics (NASDAQ: CRSP) has signed a deal with Capsida Biotherapeutics, a gene therapy player specializing in AAV engineering, to carve out a delivery mechanism for the company’s gene-editing technology in familial amyotrophic lateral sclerosis (ALS) and rare neurodegenerative disorder Friedreich’s ataxia.

  • As part of the agreement, Capsida will pick up R&D responsibilities for the ALS program and chip away at capsid design for both programs. Meanwhile, CRISPR will manage R&D for the FA program and develop gene-editing candidates for both.

  • Both companies will hold options to co-development and -commercialization rights for the program which the partner company leads.

  • The financial terms of the deal were not disclosed.

  • If one of the partners opts, the two firms would share R&D and commercialization costs and profits on that program.

  • Capsida, with its experience in AAV production, will handle clinical and commercial manufacturing, if it reaches that point.

  • Price Action: CRSP shares are trading up 0.57% at $129.50 in the premarket session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.